AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform... Show more
ANTX is expected to report earnings to rise 41.67% to -25 cents per share on March 31
Q4'26
Est.
$-0.25
Q2'26
Beat
by $0.05
Q1'26
Missed
by $0.06
Q4'25
Missed
by $0.07
Q3'25
Est.
$-0.31
The last earnings report on August 11 showed earnings per share of -18 cents, beating the estimate of -23 cents. With 582.00 shares outstanding, the current market capitalization sits at 150.94M.